RXRX vs. VCEL, BCRX, KYMR, SWTX, IOVA, ACLX, RLAY, PRME, SANA, and IBRX
Should you be buying Recursion Pharmaceuticals stock or one of its competitors? The main competitors of Recursion Pharmaceuticals include Vericel (VCEL), BioCryst Pharmaceuticals (BCRX), Kymera Therapeutics (KYMR), SpringWorks Therapeutics (SWTX), Iovance Biotherapeutics (IOVA), Arcellx (ACLX), Relay Therapeutics (RLAY), Prime Medicine (PRME), Sana Biotechnology (SANA), and ImmunityBio (IBRX). These companies are all part of the "biological products, except diagnostic" industry.
Recursion Pharmaceuticals vs.
Recursion Pharmaceuticals (NASDAQ:RXRX) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, analyst recommendations, dividends, community ranking, valuation, risk, institutional ownership and earnings.
63.6% of Recursion Pharmaceuticals shares are held by institutional investors. 22.3% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 6.4% of Vericel shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Vericel has a net margin of -10.11% compared to Recursion Pharmaceuticals' net margin of -533.45%. Vericel's return on equity of -9.26% beat Recursion Pharmaceuticals' return on equity.
Vericel received 314 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 62.81% of users gave Vericel an outperform vote while only 41.38% of users gave Recursion Pharmaceuticals an outperform vote.
Recursion Pharmaceuticals has a beta of -0.43, meaning that its stock price is 143% less volatile than the S&P 500. Comparatively, Vericel has a beta of 1.77, meaning that its stock price is 77% more volatile than the S&P 500.
In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Vericel. MarketBeat recorded 6 mentions for Recursion Pharmaceuticals and 3 mentions for Vericel. Vericel's average media sentiment score of 1.30 beat Recursion Pharmaceuticals' score of 1.05 indicating that Vericel is being referred to more favorably in the news media.
Vericel has higher revenue and earnings than Recursion Pharmaceuticals. Vericel is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Recursion Pharmaceuticals currently has a consensus target price of $12.40, suggesting a potential upside of 38.86%. Vericel has a consensus target price of $37.25, suggesting a potential upside of 11.03%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Vericel.
Summary
Vericel beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Recursion Pharmaceuticals Competitors List
Related Companies and Tools